Electrical stimulation and exercise for muscle loss in cirrhosis
Part of Brain & nervous system, Digestive system clinical trials.
This study tests whether combining electrical stimulation with exercise can help prevent muscle loss in people with cirrhosis caused by alcohol who are in the hospital. It may help you maintain strength during your stay.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be hospitalized with cirrhosis caused by alcohol.
- You must be able to do a sit-to-stand test in a certain time range for your age.
- Your handgrip strength must be at least 16 kilograms for women or 27 kilograms for men.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a neuromuscular electrical stimulation therapy helps people with sarcopenia (muscle loss). It may improve muscle strength and function.
This study tests if physical therapy can help older adults with low muscle strength and mass (sarcopenia). It might improve your ability to do daily activities.
This trial tests whether a special nutrition plan can help treat muscle loss in people with liver cirrhosis who also have fluid buildup that doesn't improve with standard treatment. It aims to improve strength and outcomes after a procedure to place a shunt in the liver.
This study tests if whole-body electrical muscle stimulation exercise helps improve nerve signals to muscles in older adults. It compares older participants (65+) with younger ones (18-39) to see how this type of exercise affects muscle activation.
This study tests whether taking a daily drink of branched-chain amino acids (a type of protein) can help people with liver cirrhosis who have lost muscle strength and mass. It may help improve muscle size and function.
This study looks at how loss of muscle strength or mass (sarcopenia) relates to advanced liver disease. It may help doctors understand which patients are at higher risk and could guide future care choices.
Hear when a new Sarcopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.